DNA methylation and repressive histones in the promoters of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, PD-L1, and galectin-9 genes in human colorectal cancer

被引：0

作者：

Varun Sasidharan Nair

Salman M. Toor

Rowaida Z. Taha

Hibah Shaath

Eyad Elkord

机构：

[1] Qatar Foundation,Cancer Research Center, Qatar Biomedical Research Institute, College of Science and Engineering, Hamad Bin Khalifa University

[2] Institute of Cancer Sciences,undefined

[3] University of Manchester,undefined

来源：

Clinical Epigenetics | 2018年 / 10卷

关键词：

Colorectal cancer; Immune checkpoints; PD-L1; Galectin-9; DNA methylation; Histone trimethylation;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

共 50 条

[21] Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Riyao Yang
Linlin Sun
Ching-Fei Li
Yu-Han Wang
Jun Yao
Hui Li
Meisi Yan
Wei-Chao Chang
Jung-Mao Hsu
Jong-Ho Cha
Jennifer L. Hsu
Cheng-Wei Chou
Xian Sun
Yalan Deng
Chao-Kai Chou
Dihua Yu
Mien-Chie Hung
Nature Communications, 12
[22] Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Yang, Riyao
Sun, Linlin
Li, Ching-Fei
Wang, Yu-Han
Yao, Jun
Li, Hui
Yan, Meisi
Chang, Wei-Chao
Hsu, Jung-Mao
Cha, Jong-Ho
Hsu, Jennifer L.
Chou, Cheng-Wei
Sun, Xian
Deng, Yalan
Chou, Chao-Kai
Yu, Dihua
Hung, Mien-Chie
NATURE COMMUNICATIONS, 2021, 12 (01)
[23] Combined inhibition of PD-1/PD-L1, Lag-3, and Tim-3 axes augments antitumor immunity in gastric cancer-T cell coculture models
Mimura, Kosaku
Kua, Ley-Fang
Xiao, Jin-Fen
Asuncion, Bernadette Reyna
Nakayama, Yuko
Syn, Nicholas
Fazreen, Zul
Soong, Richie
Kono, Koji
Yong, Wei-Peng
GASTRIC CANCER, 2021, 24 (03) : 611 - 623
[24] Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients
Kgokolo, Mahlatse C. M.
Anderson, Katherine
Siwele, Shalate C.
Steel, Helen C.
Kwofie, Luyanda L. I.
Sathekge, Mike M.
Meyer, Pieter W. A.
Rapoport, Bernardo L.
Anderson, Ronald
FRONTIERS IN ONCOLOGY, 2022, 12
[25] Investigation of immune checkpoint molecules (CTLA-4, PD-1, PD-L1, Tim-3) expressions in preeclampsia: A comparative study of membranous and soluble forms
Parhizkar, Forough
Soltani-Zangbar, Mohammad Sadegh
Shekari, Najibeh
Hajiesmailpoor, Zanyar
Parsania, Sara
Aghebati-Maleki, Ali
Aghebati-Maleki, Leili
HUMAN IMMUNOLOGY, 2025, 86 (03)
[26] CTLA-4, PD-1, LAG3, TIM3 and TIGIT display distinct vesicular distributions in murine T cells
Lu, Jiahe
Simonetti, Boris
Veler, Alisa
Cross, Stephen
Ruan, Xiongtao
Raj, Timsse
Dowsey, Andrew
Murphy, Robert F.
Verkade, Paul
Cullen, Pete
Wuelfing, Christoph
EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 54 : 1182 - 1182
[27] The Search for an Interesting Partner to Combine with PD-L1 Blockade in Mesothelioma: Focus on TIM-3 and LAG-3
Marcq, Elly
Van Audenaerde, Jonas R. M.
De Waele, Jorrit
Merlin, Celine
Pauwels, Patrick
van Meerbeeck, Jan P.
Fisher, Scott A.
Smits, Evelien L. J.
CANCERS, 2021, 13 (02) : 1 - 14
[28] Assessment of the expression and response of PD-1, LAG-3, and TIM-3 after neoadjuvant radiotherapy in rectal cancer
Peng, Qing-Qin
Li, Jin-Luan
Xin, Pei-Ling
Du, Kai-Xin
Lin, Xiao-Yi
Wu, Jun-Xin
Zhang, Mu-Tian
Kong, Xiang-Quan
NEOPLASMA, 2021, 68 (04) : 742 - +
[29] Immunotherapeutic strategies beyond the PD-1/PD-L1 pathway in head and neck squamous cell carcinoma - A scoping review on current developments in agents targeting TIM-3, TIGIT, LAG-3, and VISTA
Struckmeier, Ann-Kristin
Gosau, Martin
Smeets, Ralf
ORAL ONCOLOGY, 2025, 161
[30] Altered expression of TIM-3, LAG-3, IDO, PD-L1, and CTLA-4 during nimotuzumab therapy correlates with responses and prognosis of oral squamous cell carcinoma patients
Wang, Hong
Mao, Lu
Zhang, Tian
Zhang, Liming
Wu, Yuteng
Guo, Wei
Hu, Jingzhou
Ju, Houyu
Ren, Guoxin
JOURNAL OF ORAL PATHOLOGY & MEDICINE, 2019, 48 (08) : 669 - 676

← 1 2 3 4 5 →